Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Sep
04
Today In Oncology
Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer
Prostate Cancer NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo